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During the involution of lead nitrate-induced hyperplasia n rat liver a significant increase of transglutamin- 
ase activity, enzyme concentration, transglutaminase m ssenger RNA and protein-bound e-@-glutamyl)ly- 
sine (product of transglutaminase ction) coincided with programmed death (apoptosis) of hepatocytes. Im- 
munohistochemical examination showed the appearance of transglutaminase in apoptotic hepatocytes. An
increased transglutaminase level was also detected uring glucocorticoid-induced apoptosis of rat thymo- 
cytes. 
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1. INTRODUCTION 
The biochemical mechanism of programmed cell 
death (apoptosis), a basic cellular phenomenon oc- 
curring during embryonic development, normal 
cell turnover, hormone-induced atrophy, involu- 
tion of hyperplasia, elimination of preneoplastic 
cells, and regression of tumors [1-5], has not been 
fully clarified. Transglutaminases cross-link pro- 
teins through e-(7-glutamyl)lysine bonds [6]. Two 
of the transglutaminases have been shown to play 
essential roles in protecting biological integrity by 
formation of high molecular mass protein 
polymers: fibrin and ce2-plasmin inhibitor are 
cross-linked by blood coagulation factor XIII [7,8] 
as the final stage of clot formation. Cornified 
envelopes are formed by keratinocyte trans- 
glutaminase in the epidermis [9,10] during ter- 
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minal differentiation of epidermal cells. No 
definite role has been assigned to a third, tissue 
type transglutaminase [6,11-13]. Here we report 
results which suggest hat tissue transglutaminase- 
catalyzed protein cross-linking is part of the 
biochemical pathway of programmed cell death. 
2. MATERIALS AND METHODS 
Lead nitrate was injected intravenously into 
male Wistar rats in a dose of 10/zmol/100 g of 
body weight. Livers were perfused in situ, re- 
moved, weighed, then homogenized [4,14] to 
determine protein [15] and DNA [16] concentra- 
tions as well as transglutaminase activity [17]. 
Concentration of transglutaminase protein was 
assayed by a sandwich ELISA system [14]. The 
apoptotic index was calculated by screening 
formalin-fixed sections tained with haematoxylin- 
eosin [3,4]. The concentration of protein-bound e-
(7-glutamyl)lysine was determined following 
described principles [17,18]: extensive digestion of 
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the protein fraction precipitated by trichloroacetic 
acid; separation of the dipeptide by ion-exchange 
chromatography, then on a silica column by 
HPLC; modification by phenylisothiocyanate 
followed by quantitation on HPLC using a C18 
column and eluting with acetic acid/methanol; the 
presence of radioactive e-(7-glutamyl)lysine 
throughout he procedure to calculate recovery; 
applying 7-glutamylamine cyclotransferase, the 
specific enzyme for breaking e-(7-glutamyl)lysine 
[19], to identify the position of cross-linking 
during final analysis [20]. 
Total cellular RNA was isolated by the LiC1- 
urea method [21] from liver powdered under liquid 
N2. RNA samples were denatured by 45°7o for- 
mamide, spotted on nylon membrane and baked at 
82°C for 60 min under vacuum. A recombinant 
gt l l  plasmid containing 1.6 kb cDNA for mouse 
tissue transglutaminase [22] was labeled by nick- 
translation using biotin (Biotin kit, Bethesda Res. 
Lab.). After 24 h of hybridization in the presence 
of 40°7o formamide, 4 x SSC (1 x:  0.3 M NaCl, 
0.03 M Na-citrate), 5 x Denhardt's olution, 5°70 
dextran sulphate, 0.18°70 SDS, 5 mg/ml salmon 
sperm DNA blots were washed 3 times by 0.5 x 
SSC, 0.1% SDS at 56°C then developed using 
streptavidin and biotin labeled by alkaline 
phosphatase. 
Immunohistochemistry was carried out by the 
indirect immunoperoxidase method. Endogenous 
peroxidase activity was blocked by 0.1 M periodic 
acid treatment followed by 0.0207o NaBH4 reduc- 
tion. Primary antibody (affinity purified rabbit 
IgG raised against human tissue transglutaminase 
[14]) or preimmune serum was applied followed by 
horseradish peroxidase conjugated goat anti-rabbit 
IgG (Bio-Rad) developing the reaction with 
diaminobenzidine substrate. 
3. RESULTS AND DISCUSSION 
Liver hyperplasia was induced in rats by a single 
intravenous injection of the liver mitogen lead 
nitrate [4]. 3-4 days following treatment a marked 
liver enlargement with a maximum of almost wice 
the original size can be observed ue mostly to the 
increase in the number of hepatocytes [4]; the 
change is reflected in values of liver DNA content 
(fig.la). From day 5 onward, when the amount of 
lead in the liver is returning to normal values, a 
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Fig.1. DNA content, transglutaminase activity and 
quantity (a), apoptotic index and protein-bound e-('r- 
glutamyl)lysine concentration (b) in rat liver following 
intravenous injection of lead nitrate. Means _+ SE are 
shown. 
process of functional de-adaptation of the liver 
takes place, that is the cell number (liver DNA) 
returns to values observed before treatment 
(fig.la). The mechanism of the involution process 
is the initiation of controlled eath of almost every 
second hepatocyte [4]. The appearance of apop- 
totic bodies (figs lb, 3c) reaching peak values 
simultaneously with decrease of liver DNA in- 
dicates the process. Enzyme activities in serum that 
increase during liver cell cytolysis remained 
unaltered [3,4] at any time of apoptosis (not 
shown). 
Measuring transglutaminase activity in liver 
homogenates at various time intervals following 
lead nitrate administration an increase was ob- 
served starting on the third day, leveling off with 
a peak on the 5th-6th day when it was 3-4-times 
higher than that in control livers (fig.la). The ac- 
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tivity dropped on day 7, then returned to normal 
values on day 14. The maximum activity and max- 
imum incidence of apoptotic bodies (fig.l) coin- 
cided with involution. Using a sandwich ELISA 
system developed for the quantitation of tissue 
transglutaminase [14], it could be established that 
a higher level of transglutaminase protein appears 
simultaneously with increased enzyme activity 
(fig. la; numbers above closed circles). On Western 
blots of liver samples two transglutaminase bands 
could be visualized with small molecular mass dif- 
ference representing isoforms of tissue trans- 
glutaminase in rodents [23]. The intensity of both 
bands was increased when the liver samples 
undergoing apoptosis were analysed (fig.2b). The 
level of transglutaminase messenger RNA was also 
found to be higher in involuting liver as compared 
to controls or those with hyperplasia (fig.2a). This 
indicates that the induction of transglutaminase 
gene expression occurs in liver parallel to deletion 
of hepatocytes and the regulation is pretransla- 
tional. It has been shown that apoptosis depends 
upon synthesis of new RNA and protein species 
[5]. 
By immunohistochemical techniques tissue 
transglutaminase can be detected in endothelial 
cells of normal rat liver: endothelial ining of 
sinusoids gives a positive reaction (fig.3a) which is 
not observed using nonimmune serum (fig.3b). 
The presence of transglutaminase protein could 
not be demonstrated in hepatocytes of either nor- 
mal or proliferating liver. During the involution of 
lead nitrate-induced hyperplasia intracellular 
apoptotic bodies (fig.3c, arrowhead) and apoptotic 
hepatocytes (fig.3c, arrow) can be observed. An in- 
tense positive reaction of apoptotic bodies with 
anti-transglutaminase antibody was observed 
(fig.3d), i.e. the excess amount of trans- 
glutaminase detected biochemically during involu- 
tion seems to be present in the apoptotic ells. 
There is a substantial amount of e-(7- 
glutamyl)lysine in proteins of normal iver (fig. lb). 
An increase of the cross-link concentration, up to 
4-fold, was measured during involution of the 
enlarged liver. A high concentration of cross-link 
and high incidence of transglutaminase containing 
apoptotic cells coincided in time, i.e. simul- 
taneously whith increased synthesis of trans- 
glutaminase, a higher level of enzyme product was 
measured. 
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Fig.2. Transglutaminase m ssenger RNA (a) and enzyme 
protein (b) in liver samples following lead nitrate 
injection. (a) Numbers in the vertical row show the 
amount of RNA (rig) spotted. Numbers listed horizon- 
tally represent days following lead nitrate injection; C, 
control. (b) Western blot analysis was carried out as 
described [17]. Samples: H, purified human red blood 
cell transglutaminase (2 ng); G, purified guinea pig liver 
transglutaminase (3 ng); RBC, rat red blood cell extract 
following removal of hemoglobin (100/~g protein); C, 
control; 3, 5, 6, 14, liver samples (450/zg protein of 
each) obtained from animals 3, 5, 6, 14 days following 
treatment. Numbers to the right indicate positions of 
molecular mass reference (kDa) proteins. 
Transglutaminases are Ca2+-dependent enzymes 
[6,24]. It has been concluded that an increased 
Ca 2+ concentration i apoptotic ells is necessary 
for completion of the death program [25]; the ac- 
tivation of an endogenous endonuclease by Ca 2÷ is 
part of the process [2]. Apoptosis manifests itself 
by the aggregation of organelles, digestion of the 
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Fig.3. Immunohistochemical analysis of rat liver sections 4days following lead nitrate injection. 6/~m cryostat sections 
(a,b,d) fixed in absolute acetone ( -  20°C, 10 min) and 5/zm paraffin sections fixed with 4% formaldehyde (c). Except 
for c, slides are counterstained with Mayer's heamalum; c is a heamalum-eosin stained section. 
nuclei, shrinkage and fragmentation [1]. The prob- 
able consequence of transglutaminase activation is 
an extensive cross-linking of cytoplasmic and 
membrane proteins providing a way to maintain 
cellular integrity during the formation of the apo- 
ptotic bodies. Consequently, outpouring of poten- 
tially harmful intracellular molecules and 
abrogation of tissue continuity are prevented until 
phagocytosis of apoptotic bodies takes place. In 
terminally differentiating epidermal cells induction 
and activation of keratinocyte transglutaminase 
and its activation by raised intracellular Ca 2+ con- 
centrations are key elements in the formation of 
the cross-linked cornified envelope [9,10]. 
There was no change of transglutaminase level 
(table 1) during liver cell necrosis initiated with 
galactosamine [26]. Studying glucocorticoid- 
induced apoptosis of rat thymocytes trans- 
glutaminase level increased substantially in 
glucocorticoid-treated cells as compared to un- 
treated ones (table 1). 
It is concluded that the function of the 
ubiquitous tissue transglutaminase is related to its 
induction and activation as part of the biochemical 
program for deletion of cells through the process 
of apoptosis. The enzyme may be used as a marker 
to detect apoptotic ells among normal ones and it 
may serve as a tool to learn how the program of 
this basic cellular phenomenon is initiated under a 
variety of conditions including embryonic develop- 
ment, hormone-induced atrophy, normal cell turn- 
over, involution of hyperplasia, elimination of 
preneoplastic cells and regression of tumor 
[1,3,5,27]. 
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Table 1 
Amount and activity of transglutaminase in necrotic 
liver and cultured thymocytes of rats 
Experiment Time Activity Enzyme 
following (pmol/min protein 
treatment per mg) (ng/mg 
(h) protein) 
Liver 
Control 2 256.6 5.2 
12 242.2 6.1 
Galactosamine 2 224.7 6.0 
treatment 6 259.5 5.4 
12 230.4 6.0 
Thymocyte 
Control 2 40.1 1.4 
12 52.7 1.7 
Glucocorticoid 2 58.1 1.3 
treatment 4 310.9 5.6 
12 390.6 8.1 
Experimental conditions were as described by others 
[2,26]. Transglutaminase activity and concentration 
were assayed as described elsewhere [14,17]. Mean of at 
least 4 results is shown (variation coefficients were 
within 10%) 
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